Apotex
Biosimilar developer, Canada. 3 development products across 3 molecules: aflibercept, bevacizumab, denosumab.
First approval in the Atlas: Sep 2021, Bambevi, bevacizumab (HC)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved3
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Aflibercept | Aflivu | · | · | · | Jun 2025 | · | · |
| Bevacizumab | Bambevi | · | · | · | Sep 2021 | · | · |
| Denosumab | Denoza | · | · | · | Mar 2026 | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Apotex is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Filgrastim | Grastofil | HC | Apotex INC | Dec 2015 | Intas Pharmaceuticals (Apotex) |
| Pegfilgrastim | Lapelga | HC | Apotex INC | Apr 2018 | Intas Pharmaceuticals |
Chronology
- HCSep 2021Bambevi, bevacizumab
- HCJun 2025Aflivu, aflibercept
- HCMar 2026Denoza, denosumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.